Trial Momentum Builds

The most likely path is continued incremental success in the VOICE Trial, with Neuralink demonstrating reproducible speech synthesis in additional participants while refining decoding accuracy and implant durability. FDA oversight remains active but supportive because the reported benefit addresses severe paralysis and communication loss.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.